Research programme: CNS disorder therapeutics - biOasis Technologies/UCB
Latest Information Update: 06 May 2024
At a glance
- Originator UCB
- Developer biOasis Technologies; UCB
- Class Drug conjugates
- Mechanism of Action Biological transport stimulants; Transferrin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders